[go: up one dir, main page]

CR20160333A - Proteinas de fusión de interleucina-2 y usos de las mismas - Google Patents

Proteinas de fusión de interleucina-2 y usos de las mismas

Info

Publication number
CR20160333A
CR20160333A CR20160333A CR20160333A CR20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
relates
interleucine
same
treatment
Prior art date
Application number
CR20160333A
Other languages
English (en)
Inventor
Pablo Umana
Ekkehard Moessner
Laurence Bernard; Peterson
Linda; Wicker
Christian Klein
Ralf; Hosse
Original Assignee
F Hoffman-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffman-La Roche Ag filed Critical F Hoffman-La Roche Ag
Publication of CR20160333A publication Critical patent/CR20160333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere generalmente a proteínas de fusión de inmunoglobulinas e interleucina-2 (IL-2). Más particularmente, la invención se refiere a proteínas de fusión de inmunoglobulinas e IL-2 mutante que muestra propiedades mejoradas para su uso como agentes terapéuticos, por ejemplo, en el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias mediadas por el sistema inmune. Además, la presente invención se refiere a polinucleótidos que codifican dichas proteínas de fusión, y a vectores y células hospedadoras que comprenden dichos polinucleótidos. La invención se refiere además a métodos para producir las proteínas de fusión de la invención, y a métodos de uso en el tratamiento de enfermedades.
CR20160333A 2014-02-06 2015-02-04 Proteinas de fusión de interleucina-2 y usos de las mismas CR20160333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936564P 2014-02-06 2014-02-06
PCT/EP2015/052312 WO2015118016A1 (en) 2014-02-06 2015-02-04 Interleukin-2 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CR20160333A true CR20160333A (es) 2016-09-05

Family

ID=52669578

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160333A CR20160333A (es) 2014-02-06 2015-02-04 Proteinas de fusión de interleucina-2 y usos de las mismas

Country Status (32)

Country Link
US (1) US11098099B2 (es)
EP (2) EP3102595B1 (es)
JP (2) JP6306201B2 (es)
KR (2) KR20190126205A (es)
CN (2) CN105980410B (es)
AR (1) AR099289A1 (es)
AU (2) AU2015215001B2 (es)
BR (1) BR112016018288A2 (es)
CA (1) CA2931114A1 (es)
CL (1) CL2016001968A1 (es)
CR (1) CR20160333A (es)
DK (1) DK3102595T3 (es)
EA (2) EA201992609A1 (es)
ES (1) ES2704731T3 (es)
HR (1) HRP20190028T1 (es)
HU (1) HUE041530T2 (es)
IL (1) IL245484B (es)
LT (1) LT3102595T (es)
MA (1) MA39250B1 (es)
MX (2) MX370283B (es)
NZ (2) NZ760289A (es)
PE (1) PE20161324A1 (es)
PH (1) PH12016501406B1 (es)
PL (1) PL3102595T3 (es)
PT (1) PT3102595T (es)
RS (1) RS58149B1 (es)
SG (1) SG11201606369XA (es)
SI (1) SI3102595T1 (es)
TW (1) TWI671318B (es)
UA (1) UA120847C2 (es)
WO (1) WO2015118016A1 (es)
ZA (1) ZA201603262B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EA201992609A1 (ru) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN107106654B (zh) 2014-08-11 2021-06-11 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
DK3226843T3 (da) 2014-12-05 2021-08-16 Aragon Pharmaceuticals Inc Anticancersammensætninger
KR20210016479A (ko) 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
JP7292877B2 (ja) * 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
CN109952370B (zh) 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089420A1 (en) * 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
US10472405B2 (en) * 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2020005041A (es) * 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3746103A4 (en) 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3094112A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
EP3810185A4 (en) 2018-06-22 2022-03-23 Cugene Inc. INTERLEUKIN-2 VARIANTS AND METHODS OF USE THEREOF
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3854806A4 (en) 2018-09-21 2022-09-21 Innovent Biologics (Suzhou) Co., Ltd. NEW INTERLEUKIN 2 AND ASSOCIATED USE
JP7594161B2 (ja) * 2019-01-07 2024-12-04 インヒブルクス バイオサイエンシズ インコーポレイテッド 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
KR20220032569A (ko) * 2019-07-12 2022-03-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
JP7483857B2 (ja) 2019-07-26 2024-05-15 ビステラ， インコーポレイテッド インターロイキン－２作用物質およびその使用
CN115315436A (zh) 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
JP7591579B2 (ja) 2020-02-13 2024-11-28 エフ． ホフマン－ラ ロシュ アーゲー 核磁気共鳴緩和測定によってａａｖ粒子のローディング状態を決定するための方法
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4122951A4 (en) * 2020-03-19 2024-05-29 Innovent Biologics (Singapore) Pte. Ltd. INTERLEUKIN-2 MUTANT AND USE THEREOF
GB2602612B (en) 2020-05-13 2023-11-01 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
US12024559B2 (en) 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
CN116635403A (zh) * 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
AU2022227150A1 (en) 2021-02-24 2023-08-17 F. Hoffmann-La Roche Ag Regeneration and multiple use of depth filters
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
KR20240113459A (ko) * 2021-10-06 2024-07-22 일투 파마 염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
AU2022477937A1 (en) 2022-09-12 2025-04-10 Assistance Publique - Hôpitaux De Paris Interleukin-2 for use in treating autism spectrum disorder
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (de) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Ohrring
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
BR122019012028B1 (pt) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP2008521814A (ja) 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CA2694396A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binding agents directed to kdr and uses thereof - 035
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) * 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
NZ605980A (en) 2010-08-13 2015-01-30 Roche Glycart Ag Anti-fap antibodies and methods of use
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
DK2673294T3 (en) 2011-02-10 2016-05-30 Roche Glycart Ag MUTANT INTERLEUKIN-2 POLYPEPTIDES
EP3766513A1 (en) 2011-03-11 2021-01-20 Assistance Publique Hôpitaux de Paris Use of low dosage il-2 for treating vasculitis
SI2691417T1 (sl) * 2011-03-29 2018-11-30 Roche Glycart Ag FC variante protitelesa
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (en) * 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EA201992609A1 (ru) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
BR112016018288A2 (pt) 2017-10-10
IL245484A0 (en) 2016-06-30
EA034350B1 (ru) 2020-01-30
IL245484B (en) 2019-10-31
JP2017510551A (ja) 2017-04-13
JP2018102312A (ja) 2018-07-05
DK3102595T3 (en) 2019-02-04
HRP20190028T1 (hr) 2019-02-22
LT3102595T (lt) 2019-01-25
ZA201603262B (en) 2019-10-30
CN105980410A (zh) 2016-09-28
PH12016501406A1 (en) 2016-08-31
KR20160103134A (ko) 2016-08-31
AU2019264579A1 (en) 2019-12-05
JP6306201B2 (ja) 2018-04-04
PT3102595T (pt) 2019-01-11
AR099289A1 (es) 2016-07-13
EA201691576A1 (ru) 2016-12-30
EP3102595B1 (en) 2018-11-07
MX2016009687A (es) 2017-03-10
SI3102595T1 (sl) 2019-02-28
KR102042246B1 (ko) 2019-11-28
UA120847C2 (uk) 2020-02-25
MA39250B1 (fr) 2018-09-28
CL2016001968A1 (es) 2017-02-24
EP3102595A1 (en) 2016-12-14
MX370283B (es) 2019-12-09
NZ760289A (en) 2023-05-26
KR20190126205A (ko) 2019-11-08
CN105980410B (zh) 2020-02-28
ES2704731T3 (es) 2019-03-19
MA39250A1 (fr) 2018-03-30
CN111423513A (zh) 2020-07-17
CA2931114A1 (en) 2015-08-13
AU2015215001A1 (en) 2016-05-19
PL3102595T3 (pl) 2019-04-30
HUE041530T2 (hu) 2019-05-28
EA201992609A1 (ru) 2020-03-04
WO2015118016A1 (en) 2015-08-13
EP3508496A1 (en) 2019-07-10
NZ719654A (en) 2020-06-26
US11098099B2 (en) 2021-08-24
AU2015215001B2 (en) 2019-08-15
SG11201606369XA (en) 2016-09-29
PH12016501406B1 (en) 2022-04-22
RS58149B1 (sr) 2019-02-28
TWI671318B (zh) 2019-09-11
US20150218260A1 (en) 2015-08-06
PE20161324A1 (es) 2016-11-25
MX2019014695A (es) 2020-02-07
TW201534625A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
CR20160333A (es) Proteinas de fusión de interleucina-2 y usos de las mismas
PE20150752A1 (es) Proteinas de fusion de interleuquina-2 y usos de las mismas
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
PE20150645A1 (es) Proteinas de fusion de interleuquina 10 y usos de las mismas
UY36021A (es) Proteìnas fc multimèricas
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
BR112017007003A2 (pt) método para modulação de atividade de células imunes induzidas por car
ECSP18041733A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
BR112018014668A2 (pt) multímeros de fc de igg recombinante
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX375119B (es) Anticuerpos contra tau y sus usos.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX375841B (es) Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
MX2017002469A (es) Composiciones de matrices extracelulares.
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
CL2015002620A1 (es) Derivados piridin-4-ilo
CL2018002769A1 (es) Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso.
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.